0.05Open0.05Pre Close0 Volume355 Open Interest12.00Strike Price0.00Turnover322.62%IV213.80%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0610Delta0.0512Gamma76.80Leverage Ratio-0.0103Theta0.0001Rho4.68Eff Leverage0.0009Vega
uniQure NV Stock Discussion
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the firs...
No comment yet